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Abstract 
There is a growing recognition that gliomas are complex tumors composed of neoplastic and 
non-neoplastic cells, which each individually contribute to cancer formation, progression, and 
response to treatment. The majority of the non-neoplastic cells are tumor-associated 
macrophages (TAMs), either from the peripheral origin or intrinsic microglial cells, which 
create a supportive stroma for neoplastic cell expansion and invasion. TAMs are recruited to 
the glioma environment, have immune functions and can release a wide array of growth 
factors and cytokines in response to those produced by the cancer cells. TAMs facilitate 
tumor proliferation, survival, and migration. Through such iterative interactions, a unique 
tumor ecosystem is established, which offers new opportunities for therapeutic targeting.   
  
Solid cancers develop within complex tissue environments that dramatically influence tumor 
growth, transformation, and metastasis. Within the microenvironment of most solid tumors 
are various non-neoplastic cell types, including fibroblasts, immune system cells, and 
endothelial cells. Each of these stromal cell types produce growth/survival factors, 
chemokines, extracellular matrix constituents, and angiogenic molecules with the capacity to 
change the local milieu in which neoplastic cells grow and infiltrate. In the case of the most 
common brain tumor (glioma or astrocytoma), monocytes (macrophages and microglia) 
represent rich potential sources of these stromal factors. Moreover, the fact that as many as 
30-50% of the cells in gliomas are microglia or macrophages
1-4
 raises the intriguing 
possibility that targeting microglia and macrophages might emerge as an adjuvant therapy for 
these difficult to manage cancers. In this review, we discuss the current understanding of 
these critical stromal elements in glioma. 
 
Origins of glioma associated microglia and macrophages  
Microglia are the unique resident macrophages of the central nervous system (CNS). 
These mononuclear cells are distributed throughout the brain, where they are proposed to 
function as key immune effector cells of the CNS. Originally discovered and characterized 
almost a century ago by Pio Del Rio Hortega
5
, the tissue origins of microglia and the 
mechanisms regulating their homeostasis in health and disease have been debated for many 
decades
6
. Contributing to the confusion was the use of particular experimental systems, 
including chimera mice generated by bone-marrow (BM) transplantation of lethally-
irradiated recipients, and monocyte classification schemes reliant upon the expression of 
specific cell surface antigens. Using bone-marrow transplantation, investigators concluded 
that, under homeostatic conditions, a considerable percentage of microglia are replaced by 
donor-derived monocytes
7
. Similar studies have also suggested that increases in microglial 
density in response to CNS damage involve both the expansion of endogenous resident 
microglia and the active recruitment of BM-derived microglial progenitors from the 
bloodstream
8-12
. Leveraging analogous methods, other reports demonstrated little or no 
contribution to the brain microglia pool from circulating progenitors. These studies argued 
that the expansion of microglia during microgliosis (microglial activation) mainly results 
from the local expansion of existing resident microglia
13
. These seemingly contradictory 
findings were finally resolved when chimeric animals generated by parabiosis were 
employed, which does not require either irradiation or transplantation. Using two models of 
acute and chronic microglia activation (axotomy and neurodegeneration), no microglial 
recruitment from the blood circulation was found
13
. In addition, acute peripheral recruitment 
of monocytes was observed in an experimental mouse model of autoimmune encephalitis 
(EAE); however, these infiltrating cells vanished following remission and did not contribute 
to the resident microglia pool
14
.  
Importantly, recent fate-mapping studies have identified immature yolk sac 
progenitors as the predominant source of brain microglia. Using sublethally irradiated B6 
CD45.2+ newborns with hematopoietic cells isolated from CD45.1
+
 congenic mice, they 
showed that 3 months after transplantation, 95% of adult microglia remained of host origin. 
Second, they employed Cx3Cr1
GFP/+
 knock-in mice to show that myeloid cells expressing 
CD45 and the adult macrophage marker CD11b, F4/80 and CX3CR1 were detectible in the 
developing brain starting at E9.5. Third, using Csf1r-deficient mice, CSF-1R deficiency 
dramatically reduced the development of microglia, whereas the circulating monocytes were 
unimpaired. Fourth, leveraging the Rosa26
R26R-eYFP/R26R-eYFP
 reporter strain intercrossed with 
mice in which the tamoxifen-inducible MER-Cre-MER recombinase gene was under the 
control of one of the endogenous runt-related transcription factor 1 (Runx1) locus promoters, 
they found that Runx1
+
 progenitors migrate from yolk sac into the brain between E8.5 and 
E9.5, where they serve as cells of origin for microglia
15
. Lastly, microglia derived from 
primitive c-kit
+
 erythromyeloid precursors that subsequently develop into CD45
+
c-
kit
+
CX3CR1
neg
 immature cells (A1), which then mature into CD45
+
c-kit
neg
CX3CR1
+
 (A2) 
cells following CD31 downregulation and upregulation of F4/80 and colony stimulating 
factor receptor (CSF1R)16. Together, these studies collectively revealed that mouse myeloid 
progenitors from the blood do not significantly contribute to the pool of adult microglia after 
birth, establishing that the majority of adult microglia are yolk sac-derived and maintain 
themselves by virtue of longevity and limited self-renewal
13, 15, 17
. In this regard, resident 
microglia represent a distinct myeloid cell population (Fig. 1). 
Whereas the naïve CNS is occupied by resident microglia only, the diseased CNS 
presents a different picture. In many neuropathological conditions, the blood brain barrier is 
impaired, resulting in an infiltration of monocytes from the periphery. Understanding the 
differences between macrophages and microglia is critically important, as it has been well-
documented that they can react differently to various types of CNS insults. Recent studies 
using a complex parabiosis model with highly efficient permanent labeling of blood 
monocytes showed that peripheral mononuclear cells invade the inflamed CNS during EAE 
pathogenesis and play a primary role in disease progression to paralysis
14
. In the future, a 
clear distinction should be made between contributions of microglia and blood monocyte to 
disease pathogenesis, further underscoring the need to better understand the fate and origin of 
blood monocytes. 
Approaches to distinguishing between microglia and invaded monocytes have 
traditionally relied on the use of CD45 antibodies to separate resident microglia (CD45
low
) 
from macrophages of hematopoietic origin (CD45
high
)
18
. Analysis of human glioma samples 
by fluorescence-activated cell sorting has revealed that the CD45
high
 population is larger than 
the CD45
low
 population, suggesting that gliomas contain more recruited monocytes than 
microglia
19
. This concept was recently challenged by a study using irradiation chimeras, 
which demonstrated that the majority of TAMs are intrinsic microglia, and that these 
microglial cells upregulate their CD45 expression to constitute a significant proportion of the 
CD45
high
 monocyte population in gliomas
20
. In this study, the investigators protected the head 
from radiation to avoid a massive infiltration of monocytes due to a disrupted blood-brain 
barrier. Head-protected irradiation, however, might less efficiently remove all bone marrow 
cells, such as those residing in the skull bones and they could be a source of unlabeled 
monocytes mistaken for microglia. Another study using only single staining with either 
antibody for CX3CR1 or CCR2 concluded that the majority of TAMs are mainly monocyte-
derived macrophages (CCR2
+
CX3C1
-
) and, to a small extent, resident microglia (CCR2
-
CX3C1
+
) 
21
. Although interesting, the study has several limitations, which include the lack of 
lineage tracing experiments to provide evidence that macrophages were clearly derived from 
monocytes. Moreover, others have demonstrated that CX3CR1 is expressed by blood 
monocytes and that this expression is upregulated during monocyte differentiation into 
macrophages, implying that CX3CR1 does not represent a microglia-specific marker either in 
the naïve brain
22, 23
 or in the context of glioma
24
.  The discrepancies in the literature obtained 
using bone-marrow chimeras and cell surface antibodies highlight the urgent need to re-
evaluate these published conclusions and to perform lineage-tracing experiments using 
reporter mice that accurately distinguish microglia from monocytes/macrophages relative to 
their distinct roles in glioma formation, maintenance and progression (Fig. 2).  
 
TAMs and low-grade glioma 
Similar to their high-grade counterparts, the majority of World Health Organization 
(WHO) grade I and II astrocytomas contain microglia and macrophages
25
. Using CD68 and 
Iba1 antibodies, the percentage of monocytes in these low-grade tumors has been estimated at 
15-30% compared to 10-15% in normal non-neoplastic brain specimens
2
. Depending on the 
region where the tumor arises, the microglia fraction can be as high as 35-50%, as observed 
in WHO grade I pilocytic astrocytomas
1
. Interestingly, the percent of proliferating CD68
+
 
cells may be higher in WHO grade I pilocytic astrocytomas (32%) relative to malignant 
WHO grade III-IV astrocytomas (8.6-13.4%)
26
. The importance of these immune system-like 
cells to glioma behavior is further underscored by two clinical observations: The number of 
CD68
+
 cells increases with increasing malignancy grade
27
 and the recurrence-free survival of 
patients with pilocytic astrocytoma is inversely related to the percentage of CD68
+
 cells in the 
tumor
28
.  
To gain insights into the contributions of microglia to low-grade glioma biology, we 
have previously leveraged a murine model of neurofibromatosis type 1 (NF1) optic glioma. 
15-20% of children with the NF1 inherited cancer predisposition syndrome develop pilocytic 
astrocytomas involving the optic pathway
29
. These children are born with a germline NF1 
gene mutation (NF1+/-) and develop brain tumors following somatic NF1 gene inactivation 
in cells of the astroglial lineage 
1
. Similarly, Nf1+/- mice with somatic Nf1 gene inactivation 
in neuroglial progenitors develop low-grade glial neoplasms involving the optic nerve and 
chiasm
30
. As observed in their human counterparts, these murine low-grade tumors are 
infiltrated by TAMs
31
. The majority of the TAMs in Nf1 mouse optic gliomas are CD11b
high
; 
CD45
low
, thus most likely microglia
32
, which are evident early during tumorigenesis
33
. The 
role of these stromal cells in mediating glioma growth has been revealed by preclinical 
studies in which pharmacologic (minocycline, c-Jun-NH(2)-kinase inhibition) or genetic 
(gangciclovir treatment of CD11b- thymidine kinase expressing mouse line) silencing of 
microglial function results in reduced tumor proliferation
2, 34, 35
. Moreover, Nf1 optic glioma 
mice with reduced expression of a chemokine receptor responsible for directional 
macrophage migration (CX3CR1) demonstrate delayed tumor formation
32
. Collectively, these 
data establish critical functions for microglia in murine low-grade glioma formation and 
maintenance. Importantly, similar requirements for monocytes in another low-grade glial 
(Schwann) cell tumor have been reported. In these studies, mast cells and macrophages are 
stromal cell types essential for neurofibroma development and continued growth
36, 37
.  
While the mechanisms underlying microglia stimulation of low grade glioma growth 
have not been fully elucidated, Nf1+/- TAMs produce paracrine factors and chemokines 
capable of increasing Nf1-deficient astroglial cell proliferation
34
. One such chemokine, 
stroma-derived factor-1 (SDF-1 or CXCL12), is increased in Nf1+/- TAM relative to wild-
type (normal) microglia
38, 39
. SDF-1 operating through the CXCR4 receptor promotes optic 
glioma cell survival, such that CXCR4 inhibition reduces tumor growth in vivo. A more 
complete characterization of TAMs support of tumor maintenance is currently being 
performed using optimized RNA-sequencing methods
40
. 
 
TAMs and high-grade (malignant) glioma 
 
TAM activation 
Macrophages and microglia are mononuclear cell types characterized by considerable 
diversity and plasticity. As such, different types of macrophage activation have been defined 
following in vitro stimulation. The pro-inflammatory M1 phenotype is acquired after 
stimulation with TLR4 ligands and IFN-γ, while the alternative M2 phenotype occurs after 
IL-4, IL-10/IL-13 exposure
41
. Alternative macrophage activation can be further subdivided 
into M2a (Th2 responses, type II inflammation, killing of pathogens, allergy), M2b (Th2 
activation, immunoregulation), and M2c (immunoregulation, matrix deposition, tissue 
remodeling) activation states
41, 42
. These polarized subpopulations of macrophages differ with 
respect to receptor expression, effector function, and cytokine/chemokine production
43
. Since 
the definitions of these mutually-exclusive activation states are based on in vitro conditions, 
they do not translate well to the in vivo setting.  
Several studies have analyzed the expression of polarization marker genes in TAMs 
either in vitro or in vivo
44-46
. Similar to solid tumors arising in other organs, TAMs exhibit 
alternative macrophage activation, including increased production of anti-inflammatory 
molecules (e.g. TGF-β1, ARG1, and IL-10) as well as those that support tissue remodeling 
and angiogenesis (e.g. VEGF, MMP2, MMP9, and MT1-MMP). However, TAMs also 
produce pro-inflammatory molecules (e.g. TNF-α, IL1-β, and CXCL10)44, 46-50.  
Using RNA microarray analyses, the expression profiles of glioma-associated 
microglia/macrophages and microglia were compared to those from control animals obtained 
by CD11b antibody-mediated magnetic activated cell sorting. Approximately 1000 transcripts 
were differentially expressed by 2-fold or more in glioma-associated microglia/macrophages 
relative to control microglial cells. This expression pattern had only partial overlap with 
reported gene signatures for M1, M2a/b/c-polarized macrophages (Figure 3)
51
.  
In addition, other investigators have performed correlative analyses to determine 
whether the survival of patients with high-grade gliomas is associated with the expression of 
either M1 or M2 polarization-specific markers. One such M1 polarization marker, CD74, was 
found to be expressed by human TAMs, and positively correlated with increased patient 
survival
52
. In another study, F11R was established as a novel monocyte prognostic marker for 
glioblastoma that negatively correlates with patient survival and may be critical for defining a 
subpopulation of stromal cells for future potential therapeutic intervention
53
.  
Based on the current literature, it is clear that current M1 and M2 classification 
schemes are not absolute, but constitute relative definitions when studying TAMs in vivo. 
Indeed, TAMs express markers, which are typical for both, the M1 and M2 phenotype. As 
such, glioma-derived M-CSF induces a shift of microglia/macrophages towards the M2 
phenotype, which increases tumor growth
54
. Similarly, mTOR
55
 or colony stimulating factor-
1 (CSF-1)
54
 inhibition shifts to the M1 phenotype. Similar anti-tumor effects were shown by 
using dopamine or targeting miR-142-3p, which affected the M2-polarisation of TAMs
56, 57
. 
Based on these studies, the identification of targeting approaches that convert M2 
macrophages to M1 macrophages has been suggested as a potential therapeutic strategy to 
reduce glioma growth. However, other studies have suggested that M1 specific markers or 
associated pathways positively correlate with glioma growth. For example, IL1β was shown 
to promote glioma growth
24
.  Considering the plasticity and the fact that the M1 and M2 
phenotype is a classification defined in cultured macrophages, the phenotype of TAMs in 
vivo is more complex and strategies should rather focus on targeting specific pathways or 
molecules that TAMs use to interact with gliomas and promote their growth.  
 
TAM recruitment 
Microglial cell/macrophages accumulate within and around glioma tissue and acquire an 
amoeboid morphology. There are many factors which mediate microglia chemoattraction, 
including chemokines, ligands of complement receptors, neurotransmitters, and ATP. It is 
presently unclear whether there exist distinct factors that recruit intrinsic (resident) microglia  
or peripheral macrophages to the tumor. The first chemoattractant factor identified was 
monocyte chemoattractant protein-1 (MCP-1), also known as CCL2. Ectopic expression of 
CCL2 in rat glioma cells resulted in a 10-fold higher density of Ox42-positive cells in vivo 
and the tumors generated with CCL2-expressing glioma cells were more than 3 times larger 
in size, resulting in reduced rat survival
58
. The importance of MCP-1 to human glioma 
biology has recently been challenged, where a stronger correlation was observed between 
MCP-3, rather than MCP-1, expression and the density of infiltrating 
microglia/macrophages
59
.  
Hepatocyte growth factor/scatter factor (HGF/SF) released by glioma cells similarly 
functions as a chemoattractant for microglia, but this has only been shown for a microglial 
cell line
60
.  CXCL12 is another potent microglia/macrophage recruiting molecule, especially 
for attracting TAMs to hypoxic areas
61
.  In the normal brain, the receptor for the cytokine 
CX3CL1 (fractalkine), CX3CR1, is exclusively expressed by microglial cells and has been 
established as a reliable marker for in vivo microglial imaging. The CX3CL1/CX3CR1 
signaling cascade plays an important role for neuron-microglia communication, such that 
deletion of CX3CR1 impairs synapse plasticity during development
62
. Conflicting data exists 
regarding the importance of CX3CL1 in tumor-directed TAM migration
24, 63, 64
.  
The growth factor glial cell derived neurotrophic factor (GDNF) was first identified as 
a released factor from the glial cell line B49 and was found to promote the survival and 
differentiation of dopaminergic neurons. Mouse and human gliomas also secrete GDNF, 
which serves as a strong chemoattractant for microglia. When glioma cells were encapsulated 
in hollow fibers to allow for the passage of substances, but not cells, microglia accumulate 
around these fibers after brain implantation. GDNF mediated this attraction as shown by 
GDNF knockdown in the encapsulated glioma or by overexpression of GDNF in an 
encapsulated fibroblast cell line. Interestingly, the upregulation of GFAP in astrocytes around 
hollow fibers was not affected by GDNF knock-down, indicating that GDNF specifically acts 
on microglia
65
. 
Lastly, CSF-1 is released by glioma cells, where it can also function as a microglia 
chemoattractant. Treatment of mice with a blood-brain barrier-permeable CSF-1R antagonist 
reduced the density of TAMs and attenuated glioblastoma invasion in vivo
66
. Additionally, 
granulocyte-macrophage colony-stimulating factor (GM-CSF) can serve as a chemoattractant 
for microglia, as GM-CSF knockdown reduced microglia-dependent invasion in organotypic 
brain slices as well as attenuated the growth of intracranial gliomas in vivo
67
. In conclusion, 
there are many factors that can attract TAMs to the glioma (Figure 4). 
 
TAM regulation of glioma growth and migration 
The accumulation of TAMs within and around glioma has raised the question as to whether 
these mononuclear cells are bystanders or whether they actively influence glioma growth and 
invasion. Accumulating evidence indicates that TAMs promote glioma growth and invasion. 
Bettinger et al. (2002) noted that, in the presence of microglial cells, the motility of the 
murine glioma cells was increased three-fold in vitro
68
. In contrast, oligodendrocytes and 
endothelial cells only weakly promote glioma motility
68
. In situ, glioma growth can be 
monitored using organotypic brain slices. These slices can be depleted of microglia using 
liposomes filled with the toxin clodronate, resulting in reduced glioma invasion and growth
69
. 
A complementary in vivo approach entails the use of transgenic mice expressing the herpes 
simplex virus thymidine kinase gene under the control of the CD11b promoter. In the central 
nervous system, CD11b is specifically expressed by microglia. When ganciclovir was infused 
into the brain, there was a dramatic reduction in microglia number, which concomitantly 
attenuated glioma growth in vivo
48
.  
Several factors released from microglia have been reported to promote glioma 
proliferation and/or migration. Microglia synthesize and release stress inducible protein 1 
(STI1), a cellular prion protein ligand, which increases the proliferation and migration of 
glioblastomas in vitro and in vivo
70
.  In addition, microglia release epidermal growth factor 
(EGF), which also stimulates glioblastoma cell invasion
66
. This promoting activity by 
microglia is triggered by CSF-1, which is constitutively released by glioma cells. As 
described above, CSF-1 is a chemoattractant for microglia and, at the same time, converts 
microglia into a pro-tumorigenic phenotype
54
. CCL2 is another factor released from human 
glioma cell lines and acts on the CCL2 receptor (CCR2) expressed on microglia
71
. CCL2 can 
trigger the release of IL-6 from microglia, which in turn, promotes the invasiveness of glioma 
cells
72
. It should be noted that there may be species differences, as it was recently described 
that mouse microglia do not express CCR2
73
.  
Transforming growth factor-ß (TGF-ß) also increases the migration of glioma cells 
through processes that likely involve increased integrin expression and function
74
.  TGF-ß is 
predominantly released from microglia when studied in co-culture systems, such that 
blocking TGF-ß signaling impairs glioma growth
75
. In addition, TGF-ß2 induces the 
expression of matrix metalloprotease-2 (MMP-2) and suppresses the expression of tissue 
inhibitor of metalloproteinases (TIMP)-2, which degrades the extracellular matrix to promote 
glioma invasion
74
. While antagonizing TGF-ß function was initially considered as a potential 
anti-tumor therapy, it had severe side effects, since systemic inhibition or lack of TGF-β 
signaling results in acute inflammation and disruption of immune system homeostasis 
75
.  
MMP-2 enzyme is released in a pro-form, which is larger and needs to be cleaved in 
order to become active. The prominent enzyme for pro-MMP-2 cleavage is the membrane 
bound metalloprotease MT1-MMP. Under normal conditions, microglia do not elaborate 
MT1-MMP, but, when exposed to glioma cells, upregulate MT1-MMP expression. 
Microglial MT1-MMP expression then increases glioma growth in organotypic slices. In this 
regard, slices obtained from MT1-MMP- deficient mice harbor significantly smaller tumors. 
Moreover, when microglia were depleted from MT1-MMP deficient organotypic slices, 
glioma growth was further reduced, indicating that MT1-MMP is not the only glioma-
promoting factor expressed by microglia. In human glioma samples, MT1-MMP expression 
positively correlates with the increasing glioma malignancy grade
48
.  
The involvement of the Toll-like receptor (TLR) signaling cascade in glioma-
microglia interactions was initially inferred by the observation that deletion of MyD88, an 
adapter protein of most Toll-like receptors, inhibits MT1-MMP induction in microglia. Toll-
like receptors are prominent detectors of DNA fragments or bacterial cell wall components, 
important for mediating immunologic responses to pathogens 
76
. TLR2 was identified as the 
major TLR involved in triggering MT1-MMP upregulation in microglia. In this manner, 
gliomas implanted into Tlr2-deficient mice were significantly smaller, and the survival of 
these mice was prolonged. TLR2 forms heterodimers with TLR1 and TLR6, which is 
important for modulating MT1-MMP expression: Deletion of both TLR1 and TLR6 results in 
reduced MT1-MMP expression. In addition, treatment with TLR2-neutralizing antibodies 
reduced glioma-induced microglial MT1-MMP expression as well as attenuated glioma 
growth
77
.  
In a screen for endogenous ligands released from glioma cells, versican was identified 
as a candidate molecule for triggering TLR2 signaling 
78
. Versican exists as different splice 
variants, V0, V1 and V2. The V0/V1 isoforms are highly expressed in mouse and human 
gliomas, and reduced glioma versican expression is associated with decreased microglial 
MT1-MMP expression in vitro and in vivo. Furthermore, inoculation of versican-silenced 
gliomas resulted in smaller tumors and longer survival rates relative to controls. Importantly, 
the impact of versican signaling on glioma growth depends on the presence of microglia. The 
ability of glioma-produced versican to trigger increased TLR2 expression converts microglia 
into a pro-tumorigenic phenotype characterized by the up regulation of MT1-MMP and 
MMP9 expression. This feed-forward loop establishes an interdependent circuit of cellular 
interactions that increases glioma growth and invasion
79
. 
TAMs not only target glioma cells, but also affect angiogenesis to indirectly affect 
tumor growth. Signaling through the receptor for advanced glycation endproduct (RAGE) 
plays an important role in the process. RAGE ablation abrogated angiogenesis, which could 
be reconstituted with wild-type microglia or macrophages. This TAM activity correlated with 
the expression of VEGF, an important pro-angiogenic factor
80
. Figure 5 summarizes the 
possible mechanisms by which TAMs influence glioma growth. 
 
The effects of microglia/macrophages on glioma stem cells 
Glioblastomas contain a subpopulation of cells with stem cell-like properties (self-
renewal, multi-lineage differentiation) capable of reconstituting the native tumor following 
implantation into naïve hosts. These glioma stem cells (GSCs) reside within the perivascular 
niche, where they can be highly resistant to radiation and chemotherapy
81-83
. Figure 6 
illustrates the complexity and cellular composition of perivascular niche. The importance of 
GSCs to microglia attraction is underscored by the finding of a positive correlation between 
the density of GSCs and TAMs, indicating that GSCs may recruit TAMs more efficiently 
than their more differentiated neoplastic counterparts
84
. A recent study showed that GSCs 
release periostin, which accumulates in the perivascular niche. Periostin acts as a 
chemoattractant for TAMs, which is mediated by signaling through the integrin receptor 
αvβ3
21
. TAMs also influence the properties of GSCs, in that TGF-ß released from TAMs 
induce MMP-9 expression and increase GSC invasiveness
50
.  In addition, naïve microglia can 
reduce the sphere-forming ability of human stem cells to suppress glioma growth, while 
microglia or monocytes cultured from glioma patients have lost this anti-tumorigenic 
potential
85
. Supernatants from glioma stem cells likewise inhibit the phagocytosis activity of 
TAMs and induce the secretion of interleukin-10 and TGF-β186.  
 
Microglia and macrophages as targets for glioma therapy  
For several decades, our understanding of glioma biology was largely driven by 
studies focused on the genetic and molecular changes that occur within cancer cells and their 
contributions to deregulated cell growth. Over the past several years, work from numerous 
laboratories, including our own groups, has revealed that glioma growth is dependent upon 
growth regulatory signals that emanate from the tumor microenvironment. In this regard, it is 
important to recognize that brain tumors are complex microcosms in which the 
communication between neoplastic and non-neoplastic cells will influence not only 
gliomagenesis
87
, but also may modify glioma responses to standard therapy The identification 
of these glioma microenvironment-derived signals represents an initial step towards 
developing stroma-directed glioma therapies, with the longstanding goal of combining these 
therapies with neoplastic cell-targeted therapies. 
In this regard, the induction of HIF-1 following glioma radiation results in the 
recruitment of bone-marrow-derived myeloid cells, partially due to the activation of stromal 
cell-derived factor-1 (SDF-1) and its receptor, CXCR4. Activation of SDF-1/CXCR4 
promotes vasculogenesis and tumor recurrence. These findings support the notion that better 
outcomes for glioblastoma might be achieved using combination of radiotherapy and the 
clinically-approved small molecule inhibitor of CXCR4 signaling (AMD3100)
88
. These 
observations were further supported using a different glioma model, showing that tumor-
secreted SDF-1 is one important factor in radiotherapy-induced tumor invasiveness, where it 
exerts its primary effect through macrophage mobilization and tumor revascularization
89
. 
Similar observations were made when human recurrent glioblastomas were treated with anti-
angiogenic therapy. The increased TAM number correlated with poor survival, suggesting 
that TAMs may participate in the escape from anti-angiogenic therapy, and therefore 
represent a potential biomarker of resistance as well as a logical therapeutic target for 
recurrent glioblastoma treatment
90
. In support of these human correlative data, murine glioma 
studies revealed that glioblastoma resistance to anti-VEGF therapy is associated with 
increased myeloid cell infiltration
91
.  
Interfering with CSF-1 signaling is another potential approach to targeting TAM 
regulation of glioma growth. Pyontek et al. used an inhibitor of the CSF-1 receptor in a 
mouse proneural GBM model to increase survival and shrink established tumors 
54
. Periostin 
has also emerged as an interesting target to attenuate the tumor-supportive phenotype of 
TAMs by interrupting integrin αvβ₃ signaling 21. Interfering with this pathway with a 
blocking peptide impaired TAM recruitment. One could also exploit the interaction of TAMs 
with glioma initiating cells. In a drug screen, Amphotericin B was identified as a molecule 
that enhanced the microglial impact on brain tumor initiating cell (TIC) cell cycle growth 
arrest and differentiation 
85
, whereas Stat3 inhibition was shown to activate TAMs and inhibit 
glioma growth in mice 
92
.  
Minocycline, an antibiotic, interferes with the process of microglia activation. Using a 
rat model of glioma demonstrated synergistic activity when systemic BCNU (chemotherapy) 
treatment was combined with the local delivery of minocycline to impair microglia 
activation
93
. Currently, investigators at the University of Utah are recruiting patients for a 
phase I clinical trial using minocycline as adjuvant therapy (ClinicalTrials.gov Identifier: 
NCT02272270). Additionally, immunotherapy using activated natural killer (NK) cells 
combined with the antibody mAb9.2.27 directed against the proteoglycan Neuroglial-2 
(NG2) showed beneficial effects, which were partly due to a reversal of the tumor-promoting 
effects of TAMs
94
. Collectively, these studies suggest that TAMs modify the glioma response 
to standard and anti-angiogenic therapy.  
.  
Conclusions 
It is now evident that TAMs home to the evolving glioma and interact in a complex fashion 
with the tumor environment to promote glioma growth in mouse models and in human 
patients (Figure 6). However, there are still many unanswered questions. It is not clear what 
factors are truly responsible for mediating the interaction between glioma cells and 
microglia/macrophages. In this respect, we do not know how microglia and macrophages 
interact within the tumor, and whether they acquire distinct properties and execute distinct 
functions. It remains also an open question as whether TAMs acquire different functional 
phenotypes depending on individual glioma types (low-grade versus high-grade, glioblastoma 
molecular subtypes). Similarly, even within a given tumor, TAMs might interact differently 
with different neoplastic cell types (GSCs, differentiated astrocytoma cells). Nonetheless, 
after decades of applying treatments directed against the tumor cells directly, TAMs have 
emerged as novel targets for therapeutic intervention. Further investigation into the 
mechanisms and interactions between TAM populations and the variety of neoplastic and 
non-neoplastic cells in these tumors may one day yield novel glioma treatment strategies. 
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Figure Legends 
 
Fig. 1. Microglia and monocytes have distinct cellular origins. Under steady-state conditions, 
these different mononuclear cell populations reside in separate locations. In adult life, 
monocytes are generated from hematopoietic stem cells (HSCs) that differentiate into 
granulocyte-macrophage progenitors (GMPs) and then into monocyte-dendritic cell 
progenitors (MDPs). Mature Ly6C
hi
, CCR2
+
, CX3CR1
low/int 
inflammatory monocytes are 
released into the circulation, where they can migrate to tissues in response to specific 
pathological conditions. These cells can also give a rise to circulating monocytes. Microglia 
originate from yolk sac progenitors in the neuroepithelium beginning around embryonic day 
8.5 in the mouse. In the adult brain they express high levels of CX3CR1, CD11b, F4/80, low 
levels of CD45 and no CCR2. 
 
Fig. 2. Microglia and monocytes converge in high-grade glioma (HGG). HGG cells induce 
local inflammation that compromises the integrity of the blood-brain-barrier (BBB) and 
results in Ly6C
hi
, CCR2
+
, CX3CR1
low/int 
monocytes infiltrating into the tumor. Once within 
the CNS, they can differentiate into tumor-associated macrophages and become nearly 
indistinguishable from activated resident microglia. 
 
Fig. 3 Comparison of TAMs with M1 and M2a/b/c-stimulated macrophage datasets (from 
51
. 
Data sets from http://www.ebi.ac.uk/arrayexpress (Data set: E-GEOD-32690; 
95
), containing 
data of macrophages that were stimulated for 24 h in vitro into different polarization states 
(M0 (unstimulated), M1 (IFNγ + LPS), M2a (IL4), M2b (IFNγ + complexed Ig), and M2c 
(Dexamethasone)) were compared with glioma-regulated genes in a TAMs data set. A: A 
graphical representation of the overlap of upregulated genes in TAMs and the four 
macrophage data sets. The TAMs gene expression profile shows the greatest overlap with 
M1, and M2b polarized macrophages. The number of overlapping genes is indicated as 
number. B:  Using Gene Set Enrichment Analysis (GSEA)  indicate that only a minority of 
genes upregulated in TAMs were also induced in the M1 to M2c phenotype, 59.5% of the 
genes that were upregulated in TAMs were not regulated in any of the four macrophage 
phenotypes.  
  
Fig. 4. Glioma cells release several factors, which attract microglial cells and/or peripheral 
monocytes to the tumor tissue. 
 
Fig. 5. (A) Microglial cells release several factors which promote glioma cell invasion. (B) 
Microglia release TGF-ß, which triggers the release of pro-MMP2 from glioma cells. Pro-
MMP2 is then cleaved into active MMP2 by microglia-expressed MT1-MMP. Microglial 
MT1-MMP expression is stimulated by versican, which is released from glioma cells. 
Versican activates TLR2/p38-MAP-kinase signaling in microglial cells, which leads to the up 
regulation of MT1-MMP. TLR2 signaling in microglia also triggers MMP9 release. 
 
Fig. 6. Stroma-tumor interactions create a biological system comprised of feed-forward 
circuits that drive glioma growth and invasion. (A) Microglia and macrophages are recruited 
to the tumor by tumor bulk, glioma stem cells (GSCs) and endothelial cells. (B) These 
recruited and reprogrammed microglia and macrophages secrete soluble factors that both 
expand the tumor bulk and GSCs as well as (C) stimulate angiogenesis to establish a 
supportive niche for GSCs. (D) In addition, the interaction between non-neoplastic astrocytes 
and tumor cells can further support tumor growth. Lastly, each cellular component has the 
capacity to change the extracellular matrix to further facilitate glioma proliferation, survival, 
and expansion. 
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